ADMS News and Press, Adamas Pharmaceuticals Inc. From 03/05/19

Adamas Pharmaceuticals (NASDAQ: ADMS ) slumps  29%  premarket on light volume on the heels of its Q4 report that appeared to disappoint investors despite meeting preannounced Q4 results released in early January. Highlights: More news on: Adamas Pharmaceuticals, Inc., Healthc...

Adamas Pharmaceuticals, Inc. (ADMS) Q4 2018 Earnings Conference Call March 4, 2019 4:30 p.m. ET Company Participants Greg Went - Chairman and CEO Alf Merriweather - CFO Rajiv Patni - Chief Medical Officer Conference Call Participants David Amsellem - Piper Jaffray Tim Lug...

Adamas Pharma (NASDAQ: ADMS ): Q4 GAAP EPS of -$1.06 beats by $0.32 . More news on: Adamas Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

EMERYVILLE, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2018, along with key priorities for 2019.  “We are excited ...

EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, C...

EMERYVILLE, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2018 financial results on Monday, March 4, 2019, after market close. Subsequently, Adamas’ management team will h...

NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Roku, Inc. (NASDAQ:ROKU), AECOM (NYSE:ACM), 1-800 FLOWERS.COM, Inc. (N...

Amarin ( AMRN ) has been a darling of biotech investors with one of the highest bullish sentiments that I have seen on a stock. I will not go into the details of the background of this stock since I assume that you are familiar with it. Amarin's sole product Vascepa has a proprietary formulati...

Healthcare investors are enjoying a rousing start to the week after Eli Lilly announced its takeover of Loxo Oncology and the release of a multitude of preliminary 2018 results for presenters at JPMorgan's 2019 Healthcare Conference (JPM19). The SPDR S&P Biotech ETF ( XBI +4.8% ) is up...

Adamas Pharmaceuticals (NASDAQ: ADMS ) outlines key business priorities for 2019 and provided preliminary 2018 sales results for GOCOVRI (amantadine) extended release capsules. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Read more ...